Quick Facts

• Primary Use: Helps manage high blood sugar levels in adults and children (10 years and older) with type 2 diabetes.
• Therapeutic Goal: Intended to contribute to improved glycemic control.
• Administration: Used alongside appropriate dietary management and exercise.
• Combination Use: May be prescribed as a monotherapy or in combination with other agents, including insulin.

Сиофор 850 is a prescription medicine intended to support the management of type 2 diabetes mellitus. The primary role of this compound is to help improve blood sugar control in individuals whose condition is not adequately managed by lifestyle changes alone. It may be used in adult patients, particularly those who are overweight, and also in pediatric patients aged 10 years and above.

Appropriate use of this medication is designed to contribute to lowering both baseline and after-meal blood glucose levels. Healthcare providers may recommend this compound as a first-line approach. It is available for use alone (monotherapy) or in combination with other oral anti-diabetic medications or insulin to help achieve desired glycemic goals.

The eligibility for using Сиофор 850 (Metformin Hydrochloride) is strictly defined by regulatory guidelines based on age, organ function, and specific health status. The medicine is approved for use in adults and pediatric patients starting at 10 years of age diagnosed with Type 2 Diabetes Mellitus. Use in older adults requires closer monitoring of renal function due to the higher likelihood of age-related decline.

Absolute Contraindications (Who Must Not Use)

The medicine is strictly contraindicated in several specific populations to prevent serious metabolic risk. This includes patients with severe renal impairment (eGFR below 30 mL/ min/ 1.73 m^2) and those with any form of acute or chronic metabolic acidosis, such as Diabetic Ketoacidosis.

Eligibility Status	Key Conditions for Exclusion
Contraindicated	Severe Renal Impairment (eGFR < 30 mL/ min/ 1.73 m^2)
Contraindicated	Hepatic Impairment, Acute/Unstable Cardiac or Respiratory Failure
Not Recommended	Pregnancy, Breastfeeding, Initiation in Moderate Renal Impairment (eGFR 30-45 mL/ min/ 1.73 m^2)

Conditional Restrictions

Use must be temporarily discontinued before or during procedures involving iodinated contrast media or major surgery under general, spinal, or epidural anesthesia.

Metformin's interaction profile is structured by three key regulatory categories: substances that affect renal elimination, agents that alter glucose levels, and conditions that increase the risk of lactic acidosis.

---

Documented Interaction Restrictions

Classification	Interacting Substance / Condition
Temporarily Contraindicated	Iodinated Contrast Agents: Metformin must be discontinued at the time of or prior to the procedure and cannot be reinstituted until 48 hours afterward, following re-evaluation of renal function.
Contraindicated	Excessive Alcohol Intake: Potentiates the effect of Metformin on lactate metabolism, significantly increasing the risk of lactic acidosis.

---

Pharmacokinetic and Pharmacodynamic Interactions

Several medicines are officially documented to affect Metformin exposure by inhibiting the OCT2 and MATE transporters responsible for renal elimination. This includes agents like Cimetidine, Dolutegravir, Ranolazine, and Vandetanib, which increase Metformin plasma concentrations.

The regulatory label identifies pharmacodynamic interactions that either increase the risk of hypoglycemia when combined with other antidiabetic agents (e.g., Insulin or Sulfonylureas), or cause a loss of glycemic control when co-administered with products possessing intrinsic hyperglycaemic activity, such as Glucocorticoids and Thiazide Diuretics.

Furthermore, Carbonic Anhydrase Inhibitors (e.g., Topiramate) increase the risk of lactic acidosis. Population-specific cautions note that medicines that can acutely impair renal function (e.g., NSAIDs, ACE inhibitors) require careful monitoring due to the potential for Metformin accumulation.

The Molecular Core: Inhibiting Mitochondrial Complex I

Metformin's initial action occurs in the liver, where it mildly inhibits the Mitochondrial Respiratory Chain Complex I. This interference with energy metabolism leads to a shift in the cell's energy status by increasing the AMP:ATP ratio, which functions as the foundational signal for the drug's downstream effects.

Activating the Master Regulator: AMPK Signaling Cascade

The change in energy status triggers the activation of AMP-Activated Protein Kinase (AMPK), a central metabolic sensing pathway. Activated AMPK then suppresses the expression and activity of enzymes needed for hepatic gluconeogenesis, thus modulating the liver's production of glucose and producing a primary physiological consequence.

Increasing Peripheral Glucose Utilization

Metformin exerts a critical secondary action outside the liver by promoting the activity of the AMPK pathway in tissues like muscle and fat. This results in the improved translocation of GLUT4 glucose transporters to the cell surface, increasing the efficiency of glucose uptake and functionally increasing the tissue’s sensitivity to insulin.

How to Use Сиофор 850

Сиофор 850 (metformin hydrochloride) is administered exclusively via the oral route as a film-coated tablet. Proper use is determined by specific administration conditions, dose titration, and constraints based on physiological status.

The medication must be taken with meals or immediately after eating, and the daily dose is typically distributed into two or three divided doses to aid gastrointestinal tolerability. The treatment course is generally long-term for the chronic management of type 2 diabetes.

Dosing and Adjustment Patterns

The standard approach involves a gradual increase in dose (titration) over several weeks. Adult initiation typically begins with 500 mg twice daily or 850 mg once daily. The usual adult maintenance dose ranges from 1,500 mg to 2,000 mg per day, with the total daily dose not exceeding 2,550 mg to 3,000 mg.

Population Group	Administration Rule
Pediatric (Age 10+)	Maximum dose limited to 2,000 mg daily, given in 2 or 3 divided doses.
Renal Impairment	Dose adjustment is mandatory based on the estimated Glomerular Filtration Rate (eGFR), and the maximum dose is reduced according to the degree of impairment.

Procedural Constraints

Metformin must be temporarily discontinued at the time of, or prior to, the use of iodinated contrast materials or before surgery involving general anesthesia. Therapy is typically resumed only after 48 hours, provided renal function has been re-evaluated and confirmed as stable. If a dose is missed, patients are instructed to take the next scheduled dose at the usual time without doubling up to compensate for the missed one.

Research Evidence / Overview of Studies for Сиофор 850 (Metformin)

The active compound in Сиофор 850, Metformin, was studied for an extensive duration, providing a broad context for understanding its observed patterns of use. This overview focuses strictly on the structure and findings of clinical trials and scientific reviews as described in authoritative sources.

---

Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

Research into the management of T2DM constitutes the largest and longest-running body of evidence for this compound. Study types available include large-scale, Randomized Controlled Trials (RCTs), along with subsequent Observational Follow-up Studies that have tracked patient outcomes for many years after the initial trials concluded.

Outcomes related to systemic or functional imbalance were the primary focus. Researchers examined changes in glycemic biomarkers, such as HbA1c, and monitored outcomes related to long-term all-cause mortality and cardiovascular event incidence, as well as microvascular complications.

Findings describe patterns observed in the studies where individuals receiving the compound showed data show patterns related to measured changes in glucose control markers. Long-term observational follow-up described that studies monitored outcomes related to long-term all-cause mortality and cardiovascular event incidence in certain observed populations. Research highlights changes measured when the compound was used as a single therapy and in combination with other treatments, such as insulin.

---

Evidence in Specific Patient Groups

Researchers have explored the use of the compound in several distinct groups, including younger individuals and those with specific metabolic profiles. Studies monitored pediatric patients (age 10 and older) and adolescents with T2DM, focusing on outcomes related to glycemic control. Research also examined patient populations categorized as overweight or obese, where studies initially focused on patterns of response.

Data for certain groups remain insufficient. For instance, data are still emerging for the impact of the compound on the oldest adult populations (e.g., those over 75) who often have additional comorbidities, and subgroup findings are uncertain when trying to apply trial results to patients with significant kidney or liver issues.

---

What is Still Uncertain in the Research Landscape

While a robust research base exists, evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, particularly in areas outside of T2DM core treatment, such as Polycystic Ovary Syndrome (PCOS). Comparative evidence is lacking for many specific head-to-head trials against the newest classes of anti-diabetic medications, meaning many comparisons rely on indirect evidence. Long-term effects are not fully established for all endpoints across all studied populations, and research is ongoing to provide further insight into short-term changes.

Common questions about Сиофор 850 (FAQ)

Q: В чем разница между Сиофор 850 и обычным метформином?

A: Сиофор 850 is a brand name for a medicine whose active ingredient is Metformin Hydrochloride. Official documents describe Metformin Hydrochloride as the sole active component. The '850' on the product specifically refers to the milligram strength of the active ingredient contained in each tablet.

Q: Сиофор 850 и Глюкофаж — это одно и то же?

A: Both Сиофор 850 and Glucophage are brand names for medications that contain the identical active substance: Metformin Hydrochloride. While the brand name or presentation may differ by region, the core pharmacological component and its function are the same.

Q: Через сколько времени начинает действовать Сиофор 850?

A: The active ingredient in this medication begins to show measurable levels in the bloodstream shortly after administration. Regulatory pharmacokinetic data indicate that steady-state plasma concentrations (the stable level needed for full effect) are typically reached within 24 to 48 hours after regular administration begins.

Q: Изменится ли мое самочувствие сразу после начала приема Сиофор 850?

A: Subjective changes described by users are often related to the onset of common adverse reactions such as a metallic taste or gastrointestinal issues like nausea, vomiting, or diarrhea. The primary therapeutic effect, which is the improvement of blood sugar control, is more gradual and occurs over time as treatment continues.

Q: Можно ли совмещать Сиофор 850 и алкоголь?

A: Official product information states that excessive alcohol intake is contraindicated (not permitted) while taking this medication. This is due to alcohol potentiating the effect of the active ingredient on lactate metabolism, which significantly increases the risk of the rare, but serious, metabolic complication, lactic acidosis.

Q: Может ли Сиофор 850 повлиять на потерю веса?

A: The primary function of the medication is to manage blood sugar. However, studies have described an observed pattern where treatment with the active ingredient is associated with less weight gain when compared to certain other classes of antidiabetic medications.

Q: Существует ли риск привыкания к Сиофор 850?

A: The medication is classified as an antihyperglycemic agent used for metabolic control. Official regulatory sources do not describe a potential for dependence or addiction associated with the use of Metformin.

Q: Почему Сиофор 850 иногда назначают вместе с инсулином?

A: The active ingredient in Сиофор 850 works by increasing your body's sensitivity to insulin, rather than producing more of it. For individuals whose blood sugar remains high despite taking Metformin alone, it may be used in combination with insulin to help achieve adequate blood sugar control.

Q: Какие симптомы указывают на передозировку Сиофор 850?

A: The most serious risk associated with overdose is the development of lactic acidosis. Symptoms described in relation to this condition can include low blood pressure (hypotension), decreased body temperature (hypothermia), or other serious cardiovascular signs.

Q: Почему врачи часто назначают Сиофор 850?

A: The active ingredient in this medication is widely recognized in major treatment guidelines as the standard initial (first-line) medication for the management of Type 2 Diabetes Mellitus. This clinical recommendation status explains the high frequency of its prescription.

Q: Нужно ли соблюдать специальную диету, когда пьешь Сиофор 850?

A: Official prescribing information describes that this medication is intended to be used as part of a comprehensive management plan. This comprehensive plan includes specific lifestyle adjustments, such as adhering to a recommended diet and engaging in an exercise program.

Q: Правда ли, что этот препарат может помочь с синдрором поликистозных яичников (СПКЯ)?

A: The sole approved function (indication) for the active ingredient is the management of Type 2 Diabetes Mellitus. While research has examined its use in conditions like Polycystic Ovary Syndrome (PCOS), authoritative sources note that evidence quality varies outside of the primary indication.

Q: Как Сиофор 850 влияет на уровень холестерина?

A: While the primary action is on blood glucose, research has examined the impact of the active ingredient on lipid levels. Studies have described observed patterns related to measured decreases in both total cholesterol and low-density lipoprotein (LDL cholesterol).

Q: Нужно ли мне сразу прекращать пить Сиофор 850, если сахар пришел в норму?

A: Since the treatment is typically long-term for a chronic condition, abruptly stopping the medication is not advised. The documented consequence of cessation is the loss of glycemic control. The decision regarding the duration of use or discontinuation is a clinical one, determined by the prescribing healthcare provider.

Q: Может ли Сиофор 850 взаимодействовать с травами или добавками?

A: Official information notes that interactions with herbal remedies and dietary supplements are generally not formally evaluated. Regulatory bodies note the importance of fully disclosing the use of any supplements or herbs to the prescribing healthcare provider.

Q: Это лекарство отпускается по рецепту?

A: Сиофор 850 is legally classified as a prescription-only medication. Its classification means it is only available following a clinical assessment and prescription.

Q: Правда ли, что метформин, как в Сиофор 850, используется против старения?

A: The sole approved function of the active ingredient is for the management of Type 2 Diabetes Mellitus. While research is ongoing and studies have examined potential use related to cellular aging processes, this remains an area of investigation and is not an approved indication.

Q: Есть ли у Сиофор 850 какие-то редкие, но серьезные побочные эффекты?

A: Official safety information documents rare, serious adverse events. These include lactic acidosis (a severe buildup of lactate) and the potential for abnormal liver function tests or a condition known as hepatitis.

Q: Сиофор 850 можно принимать в любое время суток?

A: Administration instructions state that the medication must be taken with meals. The dose is typically distributed into two or three divided doses throughout the day to align with meal times.

Q: Есть ли особая форма Сиофор 850 с замедленным высвобождением?

A: The active ingredient (Metformin Hydrochloride) is available in both immediate-release (standard) and extended-release (slow-releasing) formulations. The availability of these different formulations may vary depending on the brand name and country.

Q: Что произойдет, если я перестану принимать Сиофор 850?

A: Abruptly stopping the medication is not advised. The documented consequence of cessation is the loss of glycemic control, which may result in a return to elevated blood sugar levels.

Q: Может ли Сиофор 850 вызвать металлический привкус во рту?

A: A metallic taste in the mouth, formally described as a taste disturbance, is listed in official safety information as a commonly reported side effect of this medication.

Q: Какие анализы показывают, что Сиофор 850 работает?

A: The effectiveness of the medication in managing blood sugar is assessed by monitoring standard clinical biomarkers. This typically includes measuring fasting plasma glucose and glycated hemoglobin ( HbA1c).

Q: Какая разница между Сиофор 500, 850 и 1000?

A: The only difference between the 500 mg, 850 mg, and 1000 mg versions of the medication is the quantity of the active ingredient, Metformin Hydrochloride, contained in a single tablet. They are different dosage strengths of the same medicine.

Q: Можно ли брать Сиофор 850 в самолет, и как его хранить в поездке?

A: Regulatory storage guidelines specify that the medicine should be kept at Controlled Room Temperature (20 C to 25 C) in a tightly sealed, light-resistant container. These conditions should be maintained while traveling.

How to Store and Dispose of Сиофор 850 (Metformin)

Official guidelines define specific conditions for storing and disposing of Metformin Hydrochloride. Storage requirements can vary by region: US regulatory standards generally require storage at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature), while some European labels state no special temperature conditions are required.

Container and Protection

The product must be kept in a tight, light-resistant container and stored out of the sight and reach of children. The container should use a child-resistant closure.

Disposal

Any unused product or waste material must be disposed of in accordance with local requirements. The medication should not be placed into household waste or wastewater unless specifically advised by a local authority.